Improved outcome in childhood acute myeloid leukemia in Singapore with the MRC AML 10 protocol

Authors

  • Ronald M. Tan MBBS,

    1. Division of Pediatric Hematology-Oncology, The Children's Medical Institute, National University Hospital, National University of Singapore, Singapore
    Search for more papers by this author
  • Thuan Chong Quah M Med (Paed),

    1. Division of Pediatric Hematology-Oncology, The Children's Medical Institute, National University Hospital, National University of Singapore, Singapore
    Search for more papers by this author
  • LeLe Aung MD,

    1. All Children's Hospital, St Petersburg, Florida
    Search for more papers by this author
  • Shen Liang MSc,

    1. Johns Hopkins Singapore International Medical Center, Singapore
    Search for more papers by this author
  • Richard C. Kirk FRCPCH,

    1. Freeman Hospital, Newcastle upon Tyne, United Kingdom
    Search for more papers by this author
  • Allen E.J. Yeoh M Med (Paed)

    Corresponding author
    1. Division of Pediatric Hematology-Oncology, The Children's Medical Institute, National University Hospital, National University of Singapore, Singapore
    • Division of Pediatric Hematology-Oncology, The Children's Medical Institute, National University Hospital, National University of Singapore, 5 Lower Kent Ridge Road, Singapore 119074.
    Search for more papers by this author

  • Institution at which work was performed: Division of Pediatric Hematology-Oncology, The Children's Medical Institute, National University Hospital, National University of Singapore.

Abstract

Background

The introduction of the United Kingdom Medical Research Council's 10th AML trial (MRC AML 10) protocol incorporating high-dose anthracycline therapy has improved outcome of children with acute myeloid leukemia (AML). In this study, we review the results of childhood AML therapy in a Singapore university hospital over the last 17 years emphasizing toxicity and outcome.

Procedure

Retrospective analysis revealed 34 children with AML between 1988 and 2003. Prior to September 1996, therapy consisted of: POG-8498 (n = 10), others (n = 9). From September 1996, all but one of 15 children received MRC AML 10 treatment.

Results

At the time of analysis, 17 had died from disease, and 17 patients were alive among whom 2 had relapsed. MRC AML 10-treated patients (n = 14) had significantly better 3-year overall, event-free, and disease-free survival (74% vs. 35%, 77% vs. 20%, 83% vs. 31%; P = 0.019, P = 0.002, and P = 0.010, respectively) and were likelier to achieve complete remission (CR) than non-MRC AML 10 patients (P = 0.102). Among patients who achieved CR, MRC AML 10-treated patients were significantly more likely to achieve CR after only one cycle of chemotherapy (P = 0.016). Hematologic toxicity was similar among the different regimens (P = 0.9).

Conclusions

These findings suggest that MRC AML 10 treatment results in significantly superior survival, without excess toxicity. Future studies should attempt to elucidate the relative importance of individual MRC AML 10 components and reduce the high cumulative anthracycline dose without compromising outcome. Pediatr Blood Cancer 2007;48:262–267. © 2006 Wiley-Liss, Inc.

Ancillary